Eales病TH细胞亚群异常及氧化应激的研究
|
摘要
目的:通过检验不同发病阶段Eales病患者血液中Th1、Th2细胞因子、氧化及抗氧化水平的变化,探讨免疫平衡、氧化及抗氧化损伤机制在Eales病发病过程中的作用,为该病的诊断、治疗及预后判定提供试验参考及理论依据。
方法:1.标本选择及处理:纳入符合Eales病诊断标准的30例患者,系首诊于解放军总医院眼科的Eales病人,全部为男性。最小年龄18岁,最大年龄45岁,平均年龄为28.47±8.03岁;随访时间为3-15年,平均为7.1年,其中:NVH组12例,全部为男性,发病年龄为19-41岁,平均为30.5±8.72岁;VH组18例,发病年龄为18-45岁,平均为26.5±12.53岁。对照组10例,均系本院工作人员。选择范围:男性,年龄在18—45岁之间,无自身免疫病及遗传病家族史,无亲缘关系,全身及眼部检查正常。糖皮质激素治疗组:共16例,男性。最小年龄24岁,最大年龄38岁,平均年龄为27.29±4.67岁;其中NVH组激素治疗患者为10例,VH组激素治疗患者为6例,随访时间为3个月。入选病例清晨7时安静、空腹状态下抽取肘静脉血约4ml,1小时内离心(4℃,3000rpm,10min),用微量移液器吸出上层血清约0.5ml,分装于Eppendorf管中,编号,-70℃保存备用,禁止反复冻融。2.本课题采用多功能液相芯片分析系统(luminex100TM),结合传统ELISA、免疫组化及荧光技术,检测了细胞因子(IL-2、4、5、10,TNF-alpha,IFN-gamma)在不同时期Eales病的水平,分析细胞因子在Eales病患者血清中的含量及其对Eales病的影响,探索Eales病发病因素与发生机制,为减少Eales病的发病率和更好地防治Eales病奠定了一定的基础。3.采用SOD、NO试剂盒分析SOD、NO在Eales病患者血清中的含量,分析氧化、抗氧化失衡对Eales病的影响4.统计分析:用SPSS13.0统计软件分析,P＜0.05认为有统计学差异,所得结果以(?)±S表示,小数点后保留4位有效数字。单因素分析运用T检验分析与Eales病可能有关的危险因素,logistic回归模型进行多因素分析,筛选可能导致Eales病的危险因素及其危险度的大小。
结果:1 IFN-gamma:NVH组Eales病人的血清IFN-gamma含量与正常对照组无显著性差异(P≥0.05);VH组Eales病人的血清IFN-gamma含量显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IFN-gamma含量显著高于正常对照组(P＜0.05];NVH组和VH组Eales病人的血清IFN-gamma含量无显著性差异(P≥0.05);NVH组、VH组Eales病人的血清IFN-gamma含量与激素治疗组无显著性差异(P≥0.05)。2IL-10:NVH组Eales病人的血清IL-10含量与正常对照组无显著性差异(P≥0.05);VHEales病人的血清IL-10含量显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IL-10含量显著高于正常对照组(P＜0.05);VH组Eales病人的血清IL-10含量显著高于NVH组(P＜0.05);NVH组Eales病人的血清IL-10含量与激素治疗组无显著性差异(P≥0.05);VH组Eales病人的血清IL-10含量显著高于激素治疗组(P＜0.05)。3 IL-2:不同时期Eales病人血液中IL-2含量与正常对照组两两比较均无统计学意义(P≥0.05)。提示IL-2不随Eales病人病情发展而有明显变化。4.IL-5:NVH组Eales病人的血清IL-5含量与正常对照组无显著性差异(P≥0.05);VH组、激素治疗病例组Eales病人的血清IL-5含量均显著高于正常对照组(P＜0.05);VHEales病人的血清IL-5含量显著高于NVH组(P＜0.05);NVH组、VH组Eales病人的血清IL-5含量均显著高于激素治疗组(P＜0.05)。5.IL-4:NVH组、VH组Eales病人的血清IL-4含量低于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IL-4含量与正常对照组无显著性差异(P≥0.05);VH组Eales病人的血清IL-4含量低于NVH组(P＜0.05);NVH组、VH组Eales病人的血清IL-4含量低于激素治疗组(P＜0.05)。6.TNF-alpha:NVH、VH组Eales病人的血清TNF-alpha含量均显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清TNF-alpha含量与正常对照组无显著性差异(P＜0.05);NVH组Eales病人的血清TNF-alpha含量显著高于VH组(P≥0.05);NVH组、VH组Eales病人的血清TNF-alpha含量均高于激素治疗组(P＜0.05)。7.SOD:不同时期Eales病人的血清SOD含量与正常对照组均有显著性差异(P＜0.05);NVH组Eales病人的血清SOD含量显著高于VH组(P＜0.05);NVH组、VH组Eales病人的血清SOD含量均显著低于激素治疗组(P＜0.05)。8.不同时期Eales病人的血清NO含量与正常对照组均有显著性差异(P＜0.05);激素治疗后血清NO含量与正常对照组差异无统计学意义(P＞0.05)。NVH组与VH组Eales病人的血清NO含量组差异无统计学意义(P＞0.05);NVH组、VH组Eales病人的血清NO含量均显著低于激素治疗组(P＜0.05)。将以上所述的免疫细胞因子赋值后带入多元线性回归模型,得到回归方程Y=6.91+3.22X。假设检验F=11.843,P=0.01,有统计学意义。最终进入回归方程的为TNF-alpha,且Eales病影响依次减弱。
结论:1:TH细胞亚群异常在Eales病的发生发展中起着重要作用2:减少Th1型细胞因子的产生,平衡Th1/Th2可减少局部T淋巴细胞聚集,进而可能治疗Eales病和改变病程。3.糖皮质激素治疗Eales病尤其是NVH患者具有显著疗效,但有些细胞因子水平仍偏高,提示疾病仍有复发的可能性。4.氧化应激与Eales病关系密切,清除自由基也可能起到治疗Eales病的功效。
Objective:to investigate changes in Th1Th2cytokine,oxidation and antioxidant ingredients in different pathological durations,then infer immune mechanism,role of oxidation and anti-oxidative damage to the Eales disease in the process and evaluate
Mathod:1.Sample selection and processing:30 Eales disease patients,first diagnosed in the Department of ophthalmology,The PLA General Hospital,all were male.Minimum age of 18-year-old,maximum age 45,The average age of 29.29±8.67 years,follow-up time for 3-15 years,an average of 7.1 years.Among that patients,12 were in NVH period group vs 18 VH patients.The age of 19-41 years old,The average age of 32.5±4.53;VH group of 20 patients,age of onset was 18-45 years old,an average of 26.5±12.53.The control group was 10 cases,all the hospital staff.They all were males,aged between 18 an 45-year-old,no autoimmune diseases and family history of genetic disease,unrelated, normal body and eye examination;Corticosteroid therapy group:a total of 16 cases,male. Minimum age of 24-year-old,maximum age of 38-year-old,The average age of 27.29±4.67 years follow-up time is 3-15 years,with an average of 6.9 years 7:00 am all selected cases were taken blood from The elbow about 4 ml at quiet,fasting state.After centrifugal (4℃,3000 rpm,10min)1 hour,sucked with micro-tips from the upper serum of blood about 0.5 ml,points installed in Eppendorf tube,numbered,-70℃saved standby to prohibit The repeated freezing and Thawing.2.The subject used liquid-chip analysis system (luminex100TM),combining traditional ELISA,immunohistochemistry and fluorescence to detect The cytokines(IL-2,4,5,10,TNF-α,IFN-γ)level in different Eales disease duration.we compared the contents of cytokines in the serum of patients with Eales and its impact on Eales disease,analyse Eales disease' risk factors and reduce the incidence of Eales disease and to find a better way to prevent and treat the disease.3.Use of SOD,NO kit to analyze the serum content of SOD,NO in The patients and the impact of oxidation, anti-oxidation imbalance of the of Eales disease
4.Statistical analysis:T test used to analysis of related risk factors,logistic regression model with multi-factor analysis of risk factors could leading to Eales disease and the risk of size.
Result:1.HIFN-γ:the results of the statistical analysis showed that in The inflammation duration,the level of serum HIFN-γwas no significant difference compared with control group(P≥0.05);VH group was significantly higher than control group(P＜0.05);glucocorticosteroid group was also significantly higher than control group(P＜0.05);NVH group and VH group was no significant difference(P≥0.05);NVH group, VH group and glucocorticosteroid cured group were no significant difference(P≥0.05). 2.IL-10:the level of serum IL-10 in NVH group was no significant difference competed with control group(P≥0.05);VH group was significantly higher than control group(P＜0.05);glucocorticosteroid group was significantly higher than the control group(P＜0.05); VH group was significantly higher than NVH group(P＜0.05);NVH Eales group and glucocorticosteroid group were no significant difference(P≥0.05);group of VH was significantly higher than glucocorticosteroid group(P＜0.05).3.IL-2:the blood level of IL-2 patients was no significant change in different periods compared with the control group(P≥0.05).IL-2 did not significant change with the development of disease.4.IL-5: The results of the statistical analysis showed that the NVH phase Eales patient's serum IL-5 in the control group and no significant difference(P≥0.05);group of VH, glucocorticosteroid cure the patient's group Eales serum IL-5 levels were significantly higher than the normal control group(P＜0.05);VH phase Eales patient's serum IL-5 was significantly higher than the NVH phase group(P＜0.05);NVH phase group,VH group of the patient's serum IL-5 levels were significantly higher than the glucocorticosteroid group (P＜0.05).5.IL-4:the level of serum IL-4 in NVH group was significant lower than the control group(P＜0.05);group of VH was significantly higher than the normal control group(P＜0.05);glucocorticosteroid group was no significant difference with the control group(P≥0.05);VH group was significantly lower than the glucocorticosteroid group (P＜0.05).6.TNF-α:The results of the statistical analysis showed that the serum TNF-αlevels in NVH group,VH group were significantly higher than the control group(P＜0.05); glucocorticosteroid group was no significant difference compared with the control group(P≥0.05);NVH group was significantly higher than VH group(P≥0.05);NVH group were higher than glucocorticosteroid group(P＜0.05).7.SOD results of the statistical analysis showed that level of serum SOD in different periods Eales of patients were significantly different with that the control group(P＜0.05);NVH group was significantly higher than VH group(P＜0.05);NVH group,VH group were significantly lower than glucocorticosteroid group(P＜0.05).8.NO results of the statistical analysis showed that level of serum NO in different periods Eales of patients were significantly different with that in the control group(P＜0.05);after glucocorticosteroid therapy serum content of NO was no significant difference with the control group(P＞0.05).VH and NVH groups were not significant difference(P＞0.05);NVH group,VH group were significantly lower than the glucocorticosteroid group(P＜0.05).
Conclusions:1:Th cell subsets plays an important role in Eales disease'development 2:Reducing Th1-produced cytokines and balance the Th1/Th2 T-lymphocytes may possibly treat the Eales disease.3.Glucocorticoid treatment of Eales disease especially in NVH group take a significant effect,but some cytokines are still on a high level,suggesting that there is still a possibility recurrence of Eales disease.4.Oxidative stress is also closely related to Eales disease;free radicals elimination may also play an important role in The treatment of Eales disease.
方法:1.标本选择及处理:纳入符合Eales病诊断标准的30例患者,系首诊于解放军总医院眼科的Eales病人,全部为男性。最小年龄18岁,最大年龄45岁,平均年龄为28.47±8.03岁;随访时间为3-15年,平均为7.1年,其中:NVH组12例,全部为男性,发病年龄为19-41岁,平均为30.5±8.72岁;VH组18例,发病年龄为18-45岁,平均为26.5±12.53岁。对照组10例,均系本院工作人员。选择范围:男性,年龄在18—45岁之间,无自身免疫病及遗传病家族史,无亲缘关系,全身及眼部检查正常。糖皮质激素治疗组:共16例,男性。最小年龄24岁,最大年龄38岁,平均年龄为27.29±4.67岁;其中NVH组激素治疗患者为10例,VH组激素治疗患者为6例,随访时间为3个月。入选病例清晨7时安静、空腹状态下抽取肘静脉血约4ml,1小时内离心(4℃,3000rpm,10min),用微量移液器吸出上层血清约0.5ml,分装于Eppendorf管中,编号,-70℃保存备用,禁止反复冻融。2.本课题采用多功能液相芯片分析系统(luminex100TM),结合传统ELISA、免疫组化及荧光技术,检测了细胞因子(IL-2、4、5、10,TNF-alpha,IFN-gamma)在不同时期Eales病的水平,分析细胞因子在Eales病患者血清中的含量及其对Eales病的影响,探索Eales病发病因素与发生机制,为减少Eales病的发病率和更好地防治Eales病奠定了一定的基础。3.采用SOD、NO试剂盒分析SOD、NO在Eales病患者血清中的含量,分析氧化、抗氧化失衡对Eales病的影响4.统计分析:用SPSS13.0统计软件分析,P＜0.05认为有统计学差异,所得结果以(?)±S表示,小数点后保留4位有效数字。单因素分析运用T检验分析与Eales病可能有关的危险因素,logistic回归模型进行多因素分析,筛选可能导致Eales病的危险因素及其危险度的大小。
结果:1 IFN-gamma:NVH组Eales病人的血清IFN-gamma含量与正常对照组无显著性差异(P≥0.05);VH组Eales病人的血清IFN-gamma含量显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IFN-gamma含量显著高于正常对照组(P＜0.05];NVH组和VH组Eales病人的血清IFN-gamma含量无显著性差异(P≥0.05);NVH组、VH组Eales病人的血清IFN-gamma含量与激素治疗组无显著性差异(P≥0.05)。2IL-10:NVH组Eales病人的血清IL-10含量与正常对照组无显著性差异(P≥0.05);VHEales病人的血清IL-10含量显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IL-10含量显著高于正常对照组(P＜0.05);VH组Eales病人的血清IL-10含量显著高于NVH组(P＜0.05);NVH组Eales病人的血清IL-10含量与激素治疗组无显著性差异(P≥0.05);VH组Eales病人的血清IL-10含量显著高于激素治疗组(P＜0.05)。3 IL-2:不同时期Eales病人血液中IL-2含量与正常对照组两两比较均无统计学意义(P≥0.05)。提示IL-2不随Eales病人病情发展而有明显变化。4.IL-5:NVH组Eales病人的血清IL-5含量与正常对照组无显著性差异(P≥0.05);VH组、激素治疗病例组Eales病人的血清IL-5含量均显著高于正常对照组(P＜0.05);VHEales病人的血清IL-5含量显著高于NVH组(P＜0.05);NVH组、VH组Eales病人的血清IL-5含量均显著高于激素治疗组(P＜0.05)。5.IL-4:NVH组、VH组Eales病人的血清IL-4含量低于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清IL-4含量与正常对照组无显著性差异(P≥0.05);VH组Eales病人的血清IL-4含量低于NVH组(P＜0.05);NVH组、VH组Eales病人的血清IL-4含量低于激素治疗组(P＜0.05)。6.TNF-alpha:NVH、VH组Eales病人的血清TNF-alpha含量均显著高于正常对照组(P＜0.05);激素治疗病例组Eales病人的血清TNF-alpha含量与正常对照组无显著性差异(P＜0.05);NVH组Eales病人的血清TNF-alpha含量显著高于VH组(P≥0.05);NVH组、VH组Eales病人的血清TNF-alpha含量均高于激素治疗组(P＜0.05)。7.SOD:不同时期Eales病人的血清SOD含量与正常对照组均有显著性差异(P＜0.05);NVH组Eales病人的血清SOD含量显著高于VH组(P＜0.05);NVH组、VH组Eales病人的血清SOD含量均显著低于激素治疗组(P＜0.05)。8.不同时期Eales病人的血清NO含量与正常对照组均有显著性差异(P＜0.05);激素治疗后血清NO含量与正常对照组差异无统计学意义(P＞0.05)。NVH组与VH组Eales病人的血清NO含量组差异无统计学意义(P＞0.05);NVH组、VH组Eales病人的血清NO含量均显著低于激素治疗组(P＜0.05)。将以上所述的免疫细胞因子赋值后带入多元线性回归模型,得到回归方程Y=6.91+3.22X。假设检验F=11.843,P=0.01,有统计学意义。最终进入回归方程的为TNF-alpha,且Eales病影响依次减弱。
结论:1:TH细胞亚群异常在Eales病的发生发展中起着重要作用2:减少Th1型细胞因子的产生,平衡Th1/Th2可减少局部T淋巴细胞聚集,进而可能治疗Eales病和改变病程。3.糖皮质激素治疗Eales病尤其是NVH患者具有显著疗效,但有些细胞因子水平仍偏高,提示疾病仍有复发的可能性。4.氧化应激与Eales病关系密切,清除自由基也可能起到治疗Eales病的功效。
Objective:to investigate changes in Th1Th2cytokine,oxidation and antioxidant ingredients in different pathological durations,then infer immune mechanism,role of oxidation and anti-oxidative damage to the Eales disease in the process and evaluate
Mathod:1.Sample selection and processing:30 Eales disease patients,first diagnosed in the Department of ophthalmology,The PLA General Hospital,all were male.Minimum age of 18-year-old,maximum age 45,The average age of 29.29±8.67 years,follow-up time for 3-15 years,an average of 7.1 years.Among that patients,12 were in NVH period group vs 18 VH patients.The age of 19-41 years old,The average age of 32.5±4.53;VH group of 20 patients,age of onset was 18-45 years old,an average of 26.5±12.53.The control group was 10 cases,all the hospital staff.They all were males,aged between 18 an 45-year-old,no autoimmune diseases and family history of genetic disease,unrelated, normal body and eye examination;Corticosteroid therapy group:a total of 16 cases,male. Minimum age of 24-year-old,maximum age of 38-year-old,The average age of 27.29±4.67 years follow-up time is 3-15 years,with an average of 6.9 years 7:00 am all selected cases were taken blood from The elbow about 4 ml at quiet,fasting state.After centrifugal (4℃,3000 rpm,10min)1 hour,sucked with micro-tips from the upper serum of blood about 0.5 ml,points installed in Eppendorf tube,numbered,-70℃saved standby to prohibit The repeated freezing and Thawing.2.The subject used liquid-chip analysis system (luminex100TM),combining traditional ELISA,immunohistochemistry and fluorescence to detect The cytokines(IL-2,4,5,10,TNF-α,IFN-γ)level in different Eales disease duration.we compared the contents of cytokines in the serum of patients with Eales and its impact on Eales disease,analyse Eales disease' risk factors and reduce the incidence of Eales disease and to find a better way to prevent and treat the disease.3.Use of SOD,NO kit to analyze the serum content of SOD,NO in The patients and the impact of oxidation, anti-oxidation imbalance of the of Eales disease
4.Statistical analysis:T test used to analysis of related risk factors,logistic regression model with multi-factor analysis of risk factors could leading to Eales disease and the risk of size.
Result:1.HIFN-γ:the results of the statistical analysis showed that in The inflammation duration,the level of serum HIFN-γwas no significant difference compared with control group(P≥0.05);VH group was significantly higher than control group(P＜0.05);glucocorticosteroid group was also significantly higher than control group(P＜0.05);NVH group and VH group was no significant difference(P≥0.05);NVH group, VH group and glucocorticosteroid cured group were no significant difference(P≥0.05). 2.IL-10:the level of serum IL-10 in NVH group was no significant difference competed with control group(P≥0.05);VH group was significantly higher than control group(P＜0.05);glucocorticosteroid group was significantly higher than the control group(P＜0.05); VH group was significantly higher than NVH group(P＜0.05);NVH Eales group and glucocorticosteroid group were no significant difference(P≥0.05);group of VH was significantly higher than glucocorticosteroid group(P＜0.05).3.IL-2:the blood level of IL-2 patients was no significant change in different periods compared with the control group(P≥0.05).IL-2 did not significant change with the development of disease.4.IL-5: The results of the statistical analysis showed that the NVH phase Eales patient's serum IL-5 in the control group and no significant difference(P≥0.05);group of VH, glucocorticosteroid cure the patient's group Eales serum IL-5 levels were significantly higher than the normal control group(P＜0.05);VH phase Eales patient's serum IL-5 was significantly higher than the NVH phase group(P＜0.05);NVH phase group,VH group of the patient's serum IL-5 levels were significantly higher than the glucocorticosteroid group (P＜0.05).5.IL-4:the level of serum IL-4 in NVH group was significant lower than the control group(P＜0.05);group of VH was significantly higher than the normal control group(P＜0.05);glucocorticosteroid group was no significant difference with the control group(P≥0.05);VH group was significantly lower than the glucocorticosteroid group (P＜0.05).6.TNF-α:The results of the statistical analysis showed that the serum TNF-αlevels in NVH group,VH group were significantly higher than the control group(P＜0.05); glucocorticosteroid group was no significant difference compared with the control group(P≥0.05);NVH group was significantly higher than VH group(P≥0.05);NVH group were higher than glucocorticosteroid group(P＜0.05).7.SOD results of the statistical analysis showed that level of serum SOD in different periods Eales of patients were significantly different with that the control group(P＜0.05);NVH group was significantly higher than VH group(P＜0.05);NVH group,VH group were significantly lower than glucocorticosteroid group(P＜0.05).8.NO results of the statistical analysis showed that level of serum NO in different periods Eales of patients were significantly different with that in the control group(P＜0.05);after glucocorticosteroid therapy serum content of NO was no significant difference with the control group(P＞0.05).VH and NVH groups were not significant difference(P＞0.05);NVH group,VH group were significantly lower than the glucocorticosteroid group(P＜0.05).
Conclusions:1:Th cell subsets plays an important role in Eales disease'development 2:Reducing Th1-produced cytokines and balance the Th1/Th2 T-lymphocytes may possibly treat the Eales disease.3.Glucocorticoid treatment of Eales disease especially in NVH group take a significant effect,but some cytokines are still on a high level,suggesting that there is still a possibility recurrence of Eales disease.4.Oxidative stress is also closely related to Eales disease;free radicals elimination may also play an important role in The treatment of Eales disease.
引文
1 Das T,Biswas J,Kumar A,et al.Eales' disease.Indian J Ophthalmol,1994,42:3-18.
2 尹正玉,魏世辉,马成,等.糖皮质激素治疗Eales病血管炎症期疗效的评价.中国实用眼科杂志,2007,25:112-115.
3 Costa E,Lima M,Alves JM,et al.Inflammation,T-Cell Phenotype,and NVH Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy.J Clin Immunol,2008.
4 Massi P,Vaccani A,Parolaro D.Cannabinoids,immune system and cytokine network.Curr Pharm Des,2006,12:3135-46.
5 Nakashima H,Akahoshi M,Masutani K.Th1/Th2 balance of SLE patients with lupus nephritis.Rinsho Byori,2006,54:706-13.
6 Dixit S,Gaur RL,Khan MA,et al.NVH antigens of Brugia malayi and their effect on rodent host Mastomys coucha.Parasite Immunol,2004,26:397-407.
7 Reiche EM,Morimoto HK,Nunes SM.Stress and depression-induced immune dysfunction:implications for the development and progression of cancer.Int Rev Psychiatry,2005,17:515-27.
8 Amick JE,Yandora KA,Bell MJ,et al.The Th1 versus Th2 cytokine profile in cerebrospinal fluid after severe traumatic brain injury in infants and children.Pediatr Crit Care Med,2001,2:260-264.
9 Fujii K,Sonoda K,Izumi K,et al.T lymphocyte subsets and Th1/Th2balance after laparoscopy-assisted distal gastrectomy.Surg Endosc,2003,17:1440-4.
10 Iwamoto S,Iwai S,Tsujiyama K,et al.TNF-alpha drives human CD14+monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol, 2007,179:1449-57.
11 Rodrigues DB, Correia D, Marra MD, et al. Cytokine serum levels in patients infected by human immunodeficiency virus with and without Trypanosoma cruzi coinfection. Rev Soc Bras Med Trop, 2005, 38:483-7.
12 Yin H, Wang S, Dai S. [Study on interferon gamma and interleukin-4 contents of plasma and cultured monoclear cell supernatants in patients with endometriosis]. Zhonghua Fu Chan Ke Za Zhi, 2000,35:327-8.
13 Young N, Mikhalkevich N, Yan Y, et al. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid glucocorticosteroid and IFN-gamma. J Immunol, 2005,175:8287-95.
14 Szodoray P, Timar O, Veres K, et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic NVH cytokines—immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol, 2006,64:336-44.
15 Aguilar Angeles D, Serrano Miranda E, Rojo Gutierrez MI, et al. Rev Alerg Mex, 2006,53:85-8.
16 Kariya S, Okano M, Hattori H, et al. TH1/TH2 and regulatory cytokines in adults with otitis media with effusion. Otol Neurotol, 2006,27:1089-93.
17 Li H, Wojciechowski W, Dell'Agnola C, et al. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients . is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol, 2006,177:3554-63.
18 Naldini A, Morena E, Filippi I, et al. Thrombin inhibits IFN-gamma production in human peripheral blood mononuclear cells by promoting a Th2 profile. J Interferon Cytokine Res, 2006,26:793-9.
19 Baker BS, Ovigne JM, Fischetti VA, et al. Reduced IFN-gamma responses associated with HLA-DR15 presentation of streptococcal cell wall proteins to dermal Th-1 cells in psoriasis.J Clin Immunol,2003,23:407-14.
20 Stern ME,Siemasko KF,Gao J,et al.Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease.Ocul Surf,2005,3:S161-4.
21 Prasse A,Germann M,Pechkovsky UV,et al.IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients.J Allergy Clin Immunol,2007,119:464-71.
22 Li L,Rossoni G,Sparatore A,et al.Anti-NVH and gastrointestinal effects of a novel diclofenac derivative.Free Radic Biol Med,2007,42:706-19.
23 Wallace GR,Kondeatis E,Vaughan RW,et al.IL-10 genotype analysis in patients with Behcet's disease.Hum Immunol,2007,68:122-7.
24 Wunderlich L,Paragh G,Wikonkal NM,et al.UVB induces a biphasic response of HIF-lalpha in cultured human keratinocytes.Exp Dermatol,2008,17:335-42.
25 Zheng L,Sharma R,Gaskin F,et al.A novel role of IL-2 in organ-specific autoimmune inflammation beyond regulatory T cell checkpoint:both IL-2 knockout and Fas mutation prolong lifespan of Scurfy mice but by different mechanisms.J Immunol,2007,179:8035-41.
26 Sredni-Kenigsbuch D.TH1/TH2 cytokines in the central nervous system.Int J Neurosci,2002,112:665-703.
27 李学民,王薇 白细胞介素2在铁粉诱发早期眼内非感染性炎性反应中对晶状体上皮细胞凋亡的影响.中华眼科杂志,2007,43:902-5.
28 de Kozak Y,Verwaerde C.Cytokines in immunotherapy of experimental uveitis.Int Rev Immunol,2002,21:231-53.
29 Barmeyer C,Horak I,Zeitz M,et al.The interleukin-2-deficient mouse model. Pathobiology, 2002,70:139-42.
30 Li-Weber M, Giaisi M, Treiber MK, et al. The anti-NVH sesquiterpene lactone parthenolide suppresses IL-4 gene expression in peripheral blood T. Eur J Immunol, 2002,32:3587-97.
31 Goodwin VJ, Sato TA, Mitchell MD, et al. Anti-NVH effects of interleukin-4, interleukin-10, and transforming growth factor-beta on human placental cells in vitro. Am J Reprod Immunol, 1998,40:319-25.
32 Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol, 1998,17:1-52.
33 Xiao W, Yu H, Zheng C. [The imbalance of Th1/Th2 cytokine expression in peripheral blood mononuclear cell from asthmatic patients and the effect of erythromycin on these cytokines]. Zhonghua Jie He He Hu Xi Za Zhi, 2000,23:347-50.
34 Rodriguez MF, Patino PJ, Montoya F, et al. Interleukin 4 and interferon-gamma secretion by antigen and mitogen-stimulated mononuclear cells in the hyper-IgE syndrome: no TH-2 cytokine pattern. Ann Allergy Asthma Immunol, 1998,81:443-7.
35 Sasama J, Vyas B, Vukmanovic-Stejic M, et al. Effect of IL-4, IFN-gamma and IL-12 on cytokine production from human CD45RA and CD45R0 CD4 T cell precursors. Int Arch Allergy Immunol, 1998,117:255-62.
36 Bradley JE, Jackson JA. Immunity, immunoregulation and the ecology of trichuriasis and ascariasis. Parasite Immunol, 2004,26:429-41.
37 Feltis BN, Reid DW, Ward C, et al. BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist. Respirology, 2004,9:507-13.
38 Kim JH, Kim BS, Lee SY, et al. Different IL-5 and IFN-gamma production from peripheral blood T-cell subsets in atopic and nonatopic asthmatic children. J Asthma, 2004,41:869-76.
39 Chung KF. NVH mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy, 2005,4:619-25.
40 Nan B, Lin P, Lumsden AB, et al. Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res, 2005,115:417-26.
41 Souza Neto JL, Araujo Filho I, Rego AC, et al. Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras, 2006,21 Suppl 4:8-12.
42 Varshavskii BIa, Trubnikov GV, Galaktipmpva LP, et al. [Oxidant-antioxidant status of patients with bronchial asthma during inhalation and systemic glucocorticoid therapy]. Ter Arkh, 2003,75:21-4.
43 Li LJ, Zhang F, Liu XM, et al. Oxidative stress related enzymes in response to chromium (VI) toxicity in Oxya chinensis (Orthoptera: Acridoidae). J Environ Sci (China), 2005,17:823-6.
44 Tsao SM, Yin MC, Liu WH. Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr Cancer, 2007,59:8-13.
45 Augustyniak A, Michalak K, Skrzydlewska E. [The action of oxidative stress induced by ethanol on the central nervous system (CNS)]. Postepy Hig Med Dosw (Online), 2005,59:464-71.
46 Colak E, Majkic-Singh N, Stankovic S, et al. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann Med, 2005,37:613-20.
47 Ramakrishnan S, Rajesh M, Sulochana KN. Eales' disease: oxidant stress and weak antioxidant defence. Indian J Ophthalmol, 2007,55:95-102.
48 Taysi S, Demircan B, Akdeniz N, et al. Oxidant/antioxidant status in men with Behcet's disease. Clin Rheumatol, 2007,26:418-22.
49 Lozano FS, Barros MB, Fresnadillo MJ, et al. Nitric oxide prevents the bacterial translocation and inhibits the systemic NVH response produced by implantation of a vascular prosthesis followed by Zymosan A. Inflamm Res, 2005,54:261-70.
50 Gupta T, Zielinska B, McHenry J, et al. IL—1 and iNOS gene expression and NO synthesis in the superior region of meniscal explants are dependent on the magnitude of compressive strains. Osteoarthritis Cartilage, 2008.
51 Arribas B, Elena Rodriguez-Cabezas M, Comalada M, et al. Evaluation of the preventative effects exerted by Lactobacillus fermentum in an experimental model of septic shock induced in mice. Br J Nutr, 2008:1-8.
52 Jeong MY, Lee JS, Lee JD, et al. A combined extract of Cinnamomi Ramulus, Anemarrhenae Rhizoma and Alpiniae Officinari Rhizoma suppresses production of nitric oxide by inhibiting NF-kappaB activation in RAW 264.7 cells. Phytother Res, 2008,22:772-7.
53 Kim MJ, Han JM, Jin YY, et al. In vitro antioxidant and anti-NVH activities of Jaceosidin from Artemisia princeps Pampanini cv. Sajabal. Arch Pharm Res, 2008,31:429-37.
54 Manju V, Balasubramanian V, Nalini N. Oxidative stress and tumor markers in cervical cancer patients. J Biochem Mol Biol Biophys, 2002,6:387-90.
55 Ungureanu D, Filip C, Artenie A, et al. Evaluation of simvastatin antioxidant effects. Rev Med Chir Soc Med Nat Iasi, 2003,107:66-71.
56 Kurtoglu E, Ugur A, Baltaci AK, et al. Effect of iron supplementation on oxidative stress and antioxidant status in iron-deficiency anemia. Biol Trace Elem Res, 2003,96:117-23.
57 Kleczkowski M, Klucinski W, Sikora J, et al. Role of the antioxidants in the protection against oxidative stress in cattle—nonenzymatic mechanisms (Part 2). Pol J Vet Sci, 2003,6:301-8.
58 Rajesh M, Sulochana KN, Coral K, et al. Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales' disease. Indian J Ophthalmol, 2004,52:139-44.
1.Das T,Biswas J,Kumar A,et al.Eales disease.Indian OphThalmol,1994;42(1):3-18
2.Atmaca LS,Idli A,Gunduz K.Visualisation of retinal vasculitis in Eales disease.Ocul lmmunol Inflamm,1993;1:41-8
3.Nagpal PN.Sharma RK.Management of Eales disease-analysis of 800cases.Asia Pae J Oph Thalmol,1998,10:11-17.
4.Charmis J.On The classification and management of The evolutionary course of Eales disease.Trans Oph Thalmol Soc UK,1965,85:157
5.Jyotrimay B,Tarun S.Eales Disease—An Updavte Survey of OphThalmol,2002,47(3):197-212
6.Biswas J,Mondkar SV,Ahuja VK.Macular involvement in Eales disease.SNEC Symposium on Macular Diseases,Singapore,1997
7.Biswas J,Therese L,Madhavan HN.Use of polymerase chain reaction in detection of mycobacterium tuberculosis complex DNA from vitreous sample Of Eales disease.Br J Oph Thalmol,1999;83:994-997.
8.Madhavan HN,Therese KL,Gunisha P,et al.Polymerase chain reaction for detection of Mycobacterium tuherculosis in epiretinal membrane in Eales disease.Invest Ophzhalmol Vis Sci 2000;41:822-825.
9.Biswas J,Raghavendran R,Pinakin G,et al.Presumed Eales disease wiTh neurologic involvemene report of Three cases.Re～iTa,2001;21:141-145.
10.Eler AW,Bontempo FA,Faruki H,et al.Peripheral retinal neovascularization(Eales disease)associated wiTh tlIe factor V Leiden mutation.Am J Ophzhalmol,1998;126:146-149.
11.Das T,Biswas J,Kumar A,et al.Eales disease.Indina J OphThalmol,2000;42(1):3-18.
12.Sexena S,Rajasingh J,Biswas S,et al.Gellular ilnlnune response to retinal S-antigen and interphotoraceptor retinoid—binding protein fragments in Eales disease patients.PaThobiology,1999,67:39
13.Raiesh,M;Sulchana,KN;Sundaram,AL.Presence of a 88 kDa Eales protein in uveitis,.MEales病 Sci Monit,2003,9(2):95-99.
14.任高英,宋琛,焦顺昌.Eales病患者血清补体免疫复合物溶解能力测定.中国实用眼科杂志,1996,14(10):588-589
15.MuThukaruppan VR,Rengarajan K,ChakkalaTh HR.Immunological status of patients of Ealess disease.Indian J Med Res,2002,90:351-359.
16.Biswas J,Naraln S,Roy S,HLA Association in Eales Disease[abstract].Invest OphThalmol Vis Sci,2003:36:363
17.马成,王瑛,魏世辉等。HLA与Eales病相关性研究。中国实用 眼科杂志。2006;3
18.Perentes Y,Chart CC,Bovey E.Massive vascular endoThelium growTh factor(VEGF)expression in Eales disease.Klin Monstsbl Augenheilkd 2002;219(4):311—314
19.Rajesh M,Ramesh A,Ravi PE,et al.Accumulation of 8-hydmxy-deoxygnanosine and its relationship wiTh antioxidant parameters in patients wiTh Eales disease:implications for antioxidant Therapy.Curr Eye Res,2003;27(2):103-110
20.Sulochana KN,Biswas J,Ramakrishnan S.Eales disease:increased Oxidation and po -mxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutaThione in vitreous.Curr Eye Res,2004;19:254—259.
21.张惠蓉,曹景泰,刘宁朴,等.视网膜增殖性疾病中表皮生长因子的放射受体定量测定.中华眼底病杂志.1996,2:91
22.杨萍,张惠蓉.视网膜静脉阻塞和Eales病患者玻璃体内皮生长因子含量测定。中华眼底病杂志,1997,13(3):171-173.
23.Armstrong D,Haztnett M,Browne R,et al.Lipid peroxide induced synThesis of eytokirte growTh factors during neovascularisation in The retina.Invest OphThalmol Vis Sci,2003,36;455.
24.Bhooma.V,Sulochana KN,Jyotirmay S.Eales disease:acumulation of reactive oxygen intermediates an dlipid peroxidesand decrease of antioxidants causing inflammation,neovascularzation and retinal damage.Current Eye Research,2001,16:91-95
25.Sulochana KN,Biswas J,Ramskrishnan S.Eales disease:increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutaThione in vitreous.Curr Eye Res,2003,19:254-259
26.Jyotrimay B,Tarun S.Eales Disease—An Updale Survey of OphThalmol,2002,47(3):197-212.
27.Sulochuna.Eale' sdisese:inceanxidation and prcoxdafion products of membrane constinents chiefly lipids and decreased antioxidant entidant enzymes and reduced glutaThioein vitroue(J)Char-Eye·RES.1999,9,19(3):254-9
28.郭光,关艳玲,朱敏.氩激光视网膜光凝治疗视网膜静脉周围炎疗效分析[J].中国实用眼科杂志,2002,20(8):614-615.
29.吕永顺,鲍永珍,黎晓新.视网膜静脉周围炎的激光治疗[J].中国实用眼科杂志,1995,13(1):30-31.
30.Jyotrimay B,Tarun S.Eales Disease-An Updale Survey of OphThalmol,2002,47(3):197-212.
31.魏世辉,张卯年等:Eales病行玻璃体切割术时玻璃体劈裂的意义及评价。中国综合临床,18:4,2002
32 黄欣.玻璃体手术治疗视网膜静脉周围炎并发症的疗效[J].中华眼底病杂志,2002,9:18.
33.金玲,马志中.玻璃体切除治疗视网膜静脉周围炎[J].眼外伤职业眼病杂志,1994,16(2):92.
34.王庆英,周忠友,陈志敏.列等视网膜静脉周围炎玻璃体出血的手术治疗[J].眼外伤职业眼病杂志,1998,20(2):1.
35.Shanmugam MP,BadrinaTh SS,Gopal L'Sharma T.Long term visual results of vitrectomy for Eales disease complications.Int Oph Thalmol,1998;22:61-64.
36.Atmaca LS,Batioglu F,Atmaca Sonmez P.A long-term follow-up of Eales disease.Ocul Immunol Inflamm,2002;10(3):213-221.
2 尹正玉,魏世辉,马成,等.糖皮质激素治疗Eales病血管炎症期疗效的评价.中国实用眼科杂志,2007,25:112-115.
3 Costa E,Lima M,Alves JM,et al.Inflammation,T-Cell Phenotype,and NVH Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy.J Clin Immunol,2008.
4 Massi P,Vaccani A,Parolaro D.Cannabinoids,immune system and cytokine network.Curr Pharm Des,2006,12:3135-46.
5 Nakashima H,Akahoshi M,Masutani K.Th1/Th2 balance of SLE patients with lupus nephritis.Rinsho Byori,2006,54:706-13.
6 Dixit S,Gaur RL,Khan MA,et al.NVH antigens of Brugia malayi and their effect on rodent host Mastomys coucha.Parasite Immunol,2004,26:397-407.
7 Reiche EM,Morimoto HK,Nunes SM.Stress and depression-induced immune dysfunction:implications for the development and progression of cancer.Int Rev Psychiatry,2005,17:515-27.
8 Amick JE,Yandora KA,Bell MJ,et al.The Th1 versus Th2 cytokine profile in cerebrospinal fluid after severe traumatic brain injury in infants and children.Pediatr Crit Care Med,2001,2:260-264.
9 Fujii K,Sonoda K,Izumi K,et al.T lymphocyte subsets and Th1/Th2balance after laparoscopy-assisted distal gastrectomy.Surg Endosc,2003,17:1440-4.
10 Iwamoto S,Iwai S,Tsujiyama K,et al.TNF-alpha drives human CD14+monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol, 2007,179:1449-57.
11 Rodrigues DB, Correia D, Marra MD, et al. Cytokine serum levels in patients infected by human immunodeficiency virus with and without Trypanosoma cruzi coinfection. Rev Soc Bras Med Trop, 2005, 38:483-7.
12 Yin H, Wang S, Dai S. [Study on interferon gamma and interleukin-4 contents of plasma and cultured monoclear cell supernatants in patients with endometriosis]. Zhonghua Fu Chan Ke Za Zhi, 2000,35:327-8.
13 Young N, Mikhalkevich N, Yan Y, et al. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid glucocorticosteroid and IFN-gamma. J Immunol, 2005,175:8287-95.
14 Szodoray P, Timar O, Veres K, et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic NVH cytokines—immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol, 2006,64:336-44.
15 Aguilar Angeles D, Serrano Miranda E, Rojo Gutierrez MI, et al. Rev Alerg Mex, 2006,53:85-8.
16 Kariya S, Okano M, Hattori H, et al. TH1/TH2 and regulatory cytokines in adults with otitis media with effusion. Otol Neurotol, 2006,27:1089-93.
17 Li H, Wojciechowski W, Dell'Agnola C, et al. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients . is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol, 2006,177:3554-63.
18 Naldini A, Morena E, Filippi I, et al. Thrombin inhibits IFN-gamma production in human peripheral blood mononuclear cells by promoting a Th2 profile. J Interferon Cytokine Res, 2006,26:793-9.
19 Baker BS, Ovigne JM, Fischetti VA, et al. Reduced IFN-gamma responses associated with HLA-DR15 presentation of streptococcal cell wall proteins to dermal Th-1 cells in psoriasis.J Clin Immunol,2003,23:407-14.
20 Stern ME,Siemasko KF,Gao J,et al.Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease.Ocul Surf,2005,3:S161-4.
21 Prasse A,Germann M,Pechkovsky UV,et al.IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients.J Allergy Clin Immunol,2007,119:464-71.
22 Li L,Rossoni G,Sparatore A,et al.Anti-NVH and gastrointestinal effects of a novel diclofenac derivative.Free Radic Biol Med,2007,42:706-19.
23 Wallace GR,Kondeatis E,Vaughan RW,et al.IL-10 genotype analysis in patients with Behcet's disease.Hum Immunol,2007,68:122-7.
24 Wunderlich L,Paragh G,Wikonkal NM,et al.UVB induces a biphasic response of HIF-lalpha in cultured human keratinocytes.Exp Dermatol,2008,17:335-42.
25 Zheng L,Sharma R,Gaskin F,et al.A novel role of IL-2 in organ-specific autoimmune inflammation beyond regulatory T cell checkpoint:both IL-2 knockout and Fas mutation prolong lifespan of Scurfy mice but by different mechanisms.J Immunol,2007,179:8035-41.
26 Sredni-Kenigsbuch D.TH1/TH2 cytokines in the central nervous system.Int J Neurosci,2002,112:665-703.
27 李学民,王薇 白细胞介素2在铁粉诱发早期眼内非感染性炎性反应中对晶状体上皮细胞凋亡的影响.中华眼科杂志,2007,43:902-5.
28 de Kozak Y,Verwaerde C.Cytokines in immunotherapy of experimental uveitis.Int Rev Immunol,2002,21:231-53.
29 Barmeyer C,Horak I,Zeitz M,et al.The interleukin-2-deficient mouse model. Pathobiology, 2002,70:139-42.
30 Li-Weber M, Giaisi M, Treiber MK, et al. The anti-NVH sesquiterpene lactone parthenolide suppresses IL-4 gene expression in peripheral blood T. Eur J Immunol, 2002,32:3587-97.
31 Goodwin VJ, Sato TA, Mitchell MD, et al. Anti-NVH effects of interleukin-4, interleukin-10, and transforming growth factor-beta on human placental cells in vitro. Am J Reprod Immunol, 1998,40:319-25.
32 Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol, 1998,17:1-52.
33 Xiao W, Yu H, Zheng C. [The imbalance of Th1/Th2 cytokine expression in peripheral blood mononuclear cell from asthmatic patients and the effect of erythromycin on these cytokines]. Zhonghua Jie He He Hu Xi Za Zhi, 2000,23:347-50.
34 Rodriguez MF, Patino PJ, Montoya F, et al. Interleukin 4 and interferon-gamma secretion by antigen and mitogen-stimulated mononuclear cells in the hyper-IgE syndrome: no TH-2 cytokine pattern. Ann Allergy Asthma Immunol, 1998,81:443-7.
35 Sasama J, Vyas B, Vukmanovic-Stejic M, et al. Effect of IL-4, IFN-gamma and IL-12 on cytokine production from human CD45RA and CD45R0 CD4 T cell precursors. Int Arch Allergy Immunol, 1998,117:255-62.
36 Bradley JE, Jackson JA. Immunity, immunoregulation and the ecology of trichuriasis and ascariasis. Parasite Immunol, 2004,26:429-41.
37 Feltis BN, Reid DW, Ward C, et al. BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist. Respirology, 2004,9:507-13.
38 Kim JH, Kim BS, Lee SY, et al. Different IL-5 and IFN-gamma production from peripheral blood T-cell subsets in atopic and nonatopic asthmatic children. J Asthma, 2004,41:869-76.
39 Chung KF. NVH mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy, 2005,4:619-25.
40 Nan B, Lin P, Lumsden AB, et al. Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res, 2005,115:417-26.
41 Souza Neto JL, Araujo Filho I, Rego AC, et al. Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras, 2006,21 Suppl 4:8-12.
42 Varshavskii BIa, Trubnikov GV, Galaktipmpva LP, et al. [Oxidant-antioxidant status of patients with bronchial asthma during inhalation and systemic glucocorticoid therapy]. Ter Arkh, 2003,75:21-4.
43 Li LJ, Zhang F, Liu XM, et al. Oxidative stress related enzymes in response to chromium (VI) toxicity in Oxya chinensis (Orthoptera: Acridoidae). J Environ Sci (China), 2005,17:823-6.
44 Tsao SM, Yin MC, Liu WH. Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr Cancer, 2007,59:8-13.
45 Augustyniak A, Michalak K, Skrzydlewska E. [The action of oxidative stress induced by ethanol on the central nervous system (CNS)]. Postepy Hig Med Dosw (Online), 2005,59:464-71.
46 Colak E, Majkic-Singh N, Stankovic S, et al. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann Med, 2005,37:613-20.
47 Ramakrishnan S, Rajesh M, Sulochana KN. Eales' disease: oxidant stress and weak antioxidant defence. Indian J Ophthalmol, 2007,55:95-102.
48 Taysi S, Demircan B, Akdeniz N, et al. Oxidant/antioxidant status in men with Behcet's disease. Clin Rheumatol, 2007,26:418-22.
49 Lozano FS, Barros MB, Fresnadillo MJ, et al. Nitric oxide prevents the bacterial translocation and inhibits the systemic NVH response produced by implantation of a vascular prosthesis followed by Zymosan A. Inflamm Res, 2005,54:261-70.
50 Gupta T, Zielinska B, McHenry J, et al. IL—1 and iNOS gene expression and NO synthesis in the superior region of meniscal explants are dependent on the magnitude of compressive strains. Osteoarthritis Cartilage, 2008.
51 Arribas B, Elena Rodriguez-Cabezas M, Comalada M, et al. Evaluation of the preventative effects exerted by Lactobacillus fermentum in an experimental model of septic shock induced in mice. Br J Nutr, 2008:1-8.
52 Jeong MY, Lee JS, Lee JD, et al. A combined extract of Cinnamomi Ramulus, Anemarrhenae Rhizoma and Alpiniae Officinari Rhizoma suppresses production of nitric oxide by inhibiting NF-kappaB activation in RAW 264.7 cells. Phytother Res, 2008,22:772-7.
53 Kim MJ, Han JM, Jin YY, et al. In vitro antioxidant and anti-NVH activities of Jaceosidin from Artemisia princeps Pampanini cv. Sajabal. Arch Pharm Res, 2008,31:429-37.
54 Manju V, Balasubramanian V, Nalini N. Oxidative stress and tumor markers in cervical cancer patients. J Biochem Mol Biol Biophys, 2002,6:387-90.
55 Ungureanu D, Filip C, Artenie A, et al. Evaluation of simvastatin antioxidant effects. Rev Med Chir Soc Med Nat Iasi, 2003,107:66-71.
56 Kurtoglu E, Ugur A, Baltaci AK, et al. Effect of iron supplementation on oxidative stress and antioxidant status in iron-deficiency anemia. Biol Trace Elem Res, 2003,96:117-23.
57 Kleczkowski M, Klucinski W, Sikora J, et al. Role of the antioxidants in the protection against oxidative stress in cattle—nonenzymatic mechanisms (Part 2). Pol J Vet Sci, 2003,6:301-8.
58 Rajesh M, Sulochana KN, Coral K, et al. Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales' disease. Indian J Ophthalmol, 2004,52:139-44.
1.Das T,Biswas J,Kumar A,et al.Eales disease.Indian OphThalmol,1994;42(1):3-18
2.Atmaca LS,Idli A,Gunduz K.Visualisation of retinal vasculitis in Eales disease.Ocul lmmunol Inflamm,1993;1:41-8
3.Nagpal PN.Sharma RK.Management of Eales disease-analysis of 800cases.Asia Pae J Oph Thalmol,1998,10:11-17.
4.Charmis J.On The classification and management of The evolutionary course of Eales disease.Trans Oph Thalmol Soc UK,1965,85:157
5.Jyotrimay B,Tarun S.Eales Disease—An Updavte Survey of OphThalmol,2002,47(3):197-212
6.Biswas J,Mondkar SV,Ahuja VK.Macular involvement in Eales disease.SNEC Symposium on Macular Diseases,Singapore,1997
7.Biswas J,Therese L,Madhavan HN.Use of polymerase chain reaction in detection of mycobacterium tuberculosis complex DNA from vitreous sample Of Eales disease.Br J Oph Thalmol,1999;83:994-997.
8.Madhavan HN,Therese KL,Gunisha P,et al.Polymerase chain reaction for detection of Mycobacterium tuherculosis in epiretinal membrane in Eales disease.Invest Ophzhalmol Vis Sci 2000;41:822-825.
9.Biswas J,Raghavendran R,Pinakin G,et al.Presumed Eales disease wiTh neurologic involvemene report of Three cases.Re～iTa,2001;21:141-145.
10.Eler AW,Bontempo FA,Faruki H,et al.Peripheral retinal neovascularization(Eales disease)associated wiTh tlIe factor V Leiden mutation.Am J Ophzhalmol,1998;126:146-149.
11.Das T,Biswas J,Kumar A,et al.Eales disease.Indina J OphThalmol,2000;42(1):3-18.
12.Sexena S,Rajasingh J,Biswas S,et al.Gellular ilnlnune response to retinal S-antigen and interphotoraceptor retinoid—binding protein fragments in Eales disease patients.PaThobiology,1999,67:39
13.Raiesh,M;Sulchana,KN;Sundaram,AL.Presence of a 88 kDa Eales protein in uveitis,.MEales病 Sci Monit,2003,9(2):95-99.
14.任高英,宋琛,焦顺昌.Eales病患者血清补体免疫复合物溶解能力测定.中国实用眼科杂志,1996,14(10):588-589
15.MuThukaruppan VR,Rengarajan K,ChakkalaTh HR.Immunological status of patients of Ealess disease.Indian J Med Res,2002,90:351-359.
16.Biswas J,Naraln S,Roy S,HLA Association in Eales Disease[abstract].Invest OphThalmol Vis Sci,2003:36:363
17.马成,王瑛,魏世辉等。HLA与Eales病相关性研究。中国实用 眼科杂志。2006;3
18.Perentes Y,Chart CC,Bovey E.Massive vascular endoThelium growTh factor(VEGF)expression in Eales disease.Klin Monstsbl Augenheilkd 2002;219(4):311—314
19.Rajesh M,Ramesh A,Ravi PE,et al.Accumulation of 8-hydmxy-deoxygnanosine and its relationship wiTh antioxidant parameters in patients wiTh Eales disease:implications for antioxidant Therapy.Curr Eye Res,2003;27(2):103-110
20.Sulochana KN,Biswas J,Ramakrishnan S.Eales disease:increased Oxidation and po -mxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutaThione in vitreous.Curr Eye Res,2004;19:254—259.
21.张惠蓉,曹景泰,刘宁朴,等.视网膜增殖性疾病中表皮生长因子的放射受体定量测定.中华眼底病杂志.1996,2:91
22.杨萍,张惠蓉.视网膜静脉阻塞和Eales病患者玻璃体内皮生长因子含量测定。中华眼底病杂志,1997,13(3):171-173.
23.Armstrong D,Haztnett M,Browne R,et al.Lipid peroxide induced synThesis of eytokirte growTh factors during neovascularisation in The retina.Invest OphThalmol Vis Sci,2003,36;455.
24.Bhooma.V,Sulochana KN,Jyotirmay S.Eales disease:acumulation of reactive oxygen intermediates an dlipid peroxidesand decrease of antioxidants causing inflammation,neovascularzation and retinal damage.Current Eye Research,2001,16:91-95
25.Sulochana KN,Biswas J,Ramskrishnan S.Eales disease:increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutaThione in vitreous.Curr Eye Res,2003,19:254-259
26.Jyotrimay B,Tarun S.Eales Disease—An Updale Survey of OphThalmol,2002,47(3):197-212.
27.Sulochuna.Eale' sdisese:inceanxidation and prcoxdafion products of membrane constinents chiefly lipids and decreased antioxidant entidant enzymes and reduced glutaThioein vitroue(J)Char-Eye·RES.1999,9,19(3):254-9
28.郭光,关艳玲,朱敏.氩激光视网膜光凝治疗视网膜静脉周围炎疗效分析[J].中国实用眼科杂志,2002,20(8):614-615.
29.吕永顺,鲍永珍,黎晓新.视网膜静脉周围炎的激光治疗[J].中国实用眼科杂志,1995,13(1):30-31.
30.Jyotrimay B,Tarun S.Eales Disease-An Updale Survey of OphThalmol,2002,47(3):197-212.
31.魏世辉,张卯年等:Eales病行玻璃体切割术时玻璃体劈裂的意义及评价。中国综合临床,18:4,2002
32 黄欣.玻璃体手术治疗视网膜静脉周围炎并发症的疗效[J].中华眼底病杂志,2002,9:18.
33.金玲,马志中.玻璃体切除治疗视网膜静脉周围炎[J].眼外伤职业眼病杂志,1994,16(2):92.
34.王庆英,周忠友,陈志敏.列等视网膜静脉周围炎玻璃体出血的手术治疗[J].眼外伤职业眼病杂志,1998,20(2):1.
35.Shanmugam MP,BadrinaTh SS,Gopal L'Sharma T.Long term visual results of vitrectomy for Eales disease complications.Int Oph Thalmol,1998;22:61-64.
36.Atmaca LS,Batioglu F,Atmaca Sonmez P.A long-term follow-up of Eales disease.Ocul Immunol Inflamm,2002;10(3):213-221.